Overview

Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial

Status:
NOT_YET_RECRUITING

Trial end date:
2028-03-30

Target enrollment:

Participant gender:

Summary

This study is an investigator-initiated, prospective, multicenter, randomized, controlled, open-label, non-inferiority trial designed to evaluate the efficacy and safety of trifluridine/tipiracil plus fruquintinib versus trifluridine/tipiracil plus bevacizumab in the treatment of refractory metastatic colorectal cancer.

Phase:

PHASE2

Details

Lead Sponsor:

Sun Yat-sen University

Treatments:

Bevacizumab
HMPL-013
tipiracil
Trifluridine